Jeannie McClelland

Oral Cyclophosphamide

1 post in this topic

Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Results from the recent Scleroderma Lung Study (SLS) show that oral cyclophosphamide (CYC) is better than placebo in preventing the progression of scleroderma-related interstitial lung disease (SSc-ILD) at 12 months but is associated with adverse events. Also, the long-term balance of risk and benefit remains unclear. D Khanna. (Sage Journals) Medical Decision Making, Vol. 28, No. 6, 926-937 (2008). (Also see: Pulmonary Fibrosis)

 

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.


Jeannie McClelland

(Retired) ISN Director of Support Services

(Retired) ISN Sclero Forums Manager

(Retired) ISN Blog Manager

(Retired) ISN Assistant News Guide

(Retired) ISN Artist

International Scleroderma Network

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now